Oncolytic Virus Immunotherapy Market by Type of Virus and Application- Global Industry Analysis & Forecast to 2027
Published On : January 2021 Pages : 152 Category: Pharma & Healthcare Report Code : HC0215319
Oncolytic Virus Immunotherapy Market By Type of Virus (Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus, Others) and Application (Melanoma, Non-small Cell Lung Cancer [NSCLC], Pancreatic Cancer, Breast Cancer, and Others)- Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
The Oncolytic Virus Immunotherapy Market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period. Oncolytic Virus infects and kills cancer cells. As the infected cancer cells are destroyed by oncolysis, they release new infectious virus particles or virions to help destroy the remaining tumour.
Drivers and Restraints
Top-down and bottom-up approaches are used to validate the global Oncolytic Virus Immunotherapy Marketand estimate the market size for company, regions segments, type segments and applications (end users). In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
Regional Insights
The data for 2021 is an estimate, based on the history data and the integrated view of industry experts, manufacturers, distributors and end users etc.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- SouthAmerica
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Turkey
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- Amgen, Inc.
- Merck & Co., Inc. (Viralytics Limited)
- Shanghai Sunway Biotech Co., Ltd.
- TILT Biotherapeutics
- Oncorus, Inc.
- Replimune Group, Inc.
- OncolysBioPharma, Inc.
- Sorrento Therapeutics, Inc.
- Oncolytics Biotech, Inc.
- SillaJen, Inc.
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2021 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Oncolytic Virus Immunotherapy Market, ByType of Virus, Estimates and Forecast, 2017-2027 ($Million)
o Herpes Simplex Virus
o Vaccinia Virus
o Adenovirus
o Others
· Oncolytic Virus Immunotherapy Market, ByApplication, Estimates and Forecast, 2017-2027 ($Million)
o Melanoma
o Non-small Cell Lung Cancer [NSCLC]
o Pancreatic Cancer
o Breast Cancer
o Other
· Oncolytic Virus Immunotherapy Market, By Key Players, Estimates and Forecast, 2017-2027 ($Million)
o Amgen, Inc.
o Merck & Co., Inc. (Viralytics Limited)
o Shanghai Sunway Biotech Co., Ltd.
o TILT Biotherapeutics
o Oncorus, Inc.
o Replimune Group, Inc.
o OncolysBioPharma, Inc.
o Sorrento Therapeutics, Inc.
o Oncolytics Biotech, Inc.
o SillaJen, Inc.
· Oncolytic Virus Immunotherapy Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Oncolytic Virus Immunotherapy Market, By Country
o U.S. Oncolytic Virus Immunotherapy Market
o Canada Oncolytic Virus Immunotherapy Market
o Mexico Oncolytic Virus Immunotherapy Market
o Europe
§ Europe Oncolytic Virus Immunotherapy Market, By Country
o UK Oncolytic Virus Immunotherapy Market
o Germany Oncolytic Virus Immunotherapy Market
o France Oncolytic Virus Immunotherapy Market
o Russia Oncolytic Virus Immunotherapy Market
o Italy Oncolytic Virus Immunotherapy Market
o Rest of Europe Oncolytic Virus Immunotherapy Market
o Asia-Pacific
§ Asia-Pacific Oncolytic Virus Immunotherapy Market, By Country
o China Oncolytic Virus Immunotherapy Market
o Japan Oncolytic Virus Immunotherapy Market
o South Korea Oncolytic Virus Immunotherapy Market
o India Oncolytic Virus Immunotherapy Market
o Southeast Asia Oncolytic Virus Immunotherapy Market
o Rest of Asia-Pacific Oncolytic Virus Immunotherapy Market
o South America
§ South America Oncolytic Virus Immunotherapy Market
o Brazil Oncolytic Virus Immunotherapy Market
o Argentina Oncolytic Virus Immunotherapy Market
o Columbia Oncolytic Virus Immunotherapy Market
o Rest of South America Oncolytic Virus Immunotherapy Market
o Middle East and Africa
§ Middle East and Africa Oncolytic Virus Immunotherapy Market
o Saudi Arabia Oncolytic Virus Immunotherapy Market
o UAE Oncolytic Virus Immunotherapy Market
o Egypt Oncolytic Virus Immunotherapy Market
o Nigeria Oncolytic Virus Immunotherapy Market
o South Africa Oncolytic Virus Immunotherapy Market
o TurkeyOncolytic Virus Immunotherapy Market
o Rest of MEA Oncolytic Virus Immunotherapy Market
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Oncolytic Virus Immunotherapy Market, By Type Of Virus
5.1. Introduction
5.2. Global Oncolytic Virus Immunotherapy Revenue and Market Share by Type Of Virus (2017-2021)
5.2.1. Global Oncolytic Virus Immunotherapy Revenue and Revenue Share by Type Of Virus (2017-2021)
5.3. Herpes Simplex Virus
5.3.1. Global Herpes Simplex Virus Revenue and Growth Rate (2017-2021)
5.4. Vaccinia Virus
5.4.1. Global Vaccinia Virus Revenue and Growth Rate (2017-2021)
5.5. Adenovirus
5.5.1. Global Adenovirus Revenue and Growth Rate (2017-2021)
5.6. Reovirus
5.6.1. Global Reovirus Revenue and Growth Rate (2017-2021)
5.7. Others
5.7.1. Global Others Revenue and Growth Rate (2017-2021)
6. Oncolytic Virus Immunotherapy Market, By Applications
6.1. Introduction
6.2. Global Oncolytic Virus Immunotherapy Revenue and Market Share by Applications (2017-2021)
6.2.1. Global Oncolytic Virus Immunotherapy Revenue and Revenue Share by Applications (2017-2021)
6.3. Melanoma
6.3.1. Global Melanoma Revenue and Growth Rate (2017-2021)
6.4. Non-small Cell Lung Cancer [NSCLC]
6.4.1. Global Non-small Cell Lung Cancer [NSCLC] Revenue and Growth Rate (2017-2021)
6.5. Pancreatic Cancer
6.5.1. Global Pancreatic Cancer Revenue and Growth Rate (2017-2021)
6.6. Breast Cancer
6.6.1. Global Breast Cancer Revenue and Growth Rate (2017-2021)
6.7. Other
6.7.1. Global Other Revenue and Growth Rate (2017-2021)
7. Oncolytic Virus Immunotherapy Market, By Region
7.1. Introduction
7.2. Global Oncolytic Virus Immunotherapy Revenue and Market Share by Regions
7.2.1. Global Oncolytic Virus Immunotherapy Revenue by Regions (2017-2021)
7.3. North America Oncolytic Virus Immunotherapy by Countries
7.3.1. North America Oncolytic Virus Immunotherapy Revenue and Growth Rate (2017-2021)
7.3.2. North America Oncolytic Virus Immunotherapy Revenue (Million USD) by Countries (2017-2021)
7.3.3. United States
7.3.3.1. United States Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.3.4. Canada
7.3.4.1. Canada Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.3.5. Mexico
7.3.5.1. Mexico Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.4. Europe Oncolytic Virus Immunotherapy by Countries
7.4.1. Europe Oncolytic Virus Immunotherapy Revenue and Growth Rate (2017-2021)
7.4.2. Europe Oncolytic Virus Immunotherapy Revenue (Million USD) by Countries (2017-2021)
7.4.3. Germany
7.4.3.1. Germany Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.4. France
7.4.4.1. France Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.5. UK
7.4.5.1. UK Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.6. Russia
7.4.6.1. Russia Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.7. Italy
7.4.7.1. Italy Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.4.8. Rest of Europe
7.4.8.1. Rest of Europe Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.5. Asia-Pacific Oncolytic Virus Immunotherapy by Countries
7.5.1. Asia-Pacific Oncolytic Virus Immunotherapy Revenue and Growth Rate (2017-2021)
7.5.2. Asia-Pacific Oncolytic Virus Immunotherapy Revenue (Million USD) by Countries (2017-2021)
7.5.3. China
7.5.3.1. China Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.4. Japan
7.5.4.1. Japan Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.5. Korea
7.5.5.1. Korea Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.6. India
7.5.6.1. India Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.7. Southeast Asia
7.5.7.1. Southeast Asia Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.5.8. Rest of Asia-Pacific
7.5.8.1. Rest of Asia-Pacific Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.6. South America Oncolytic Virus Immunotherapy by Countries
7.6.1. South America Oncolytic Virus Immunotherapy Revenue and Growth Rate (2017-2021)
7.6.2. South America Oncolytic Virus Immunotherapy Revenue (Million USD) by Countries (2017-2021)
7.6.3. Brazil
7.6.3.1. Brazil Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.4. Argentina
7.6.4.1. Argentina Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.5. Columbia
7.6.5.1. Columbia Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.6.6. Rest of South America
7.6.6.1. Rest of South America Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.7. Middle East and Africa Oncolytic Virus Immunotherapy by Countries
7.7.1. Middle East and Africa Oncolytic Virus Immunotherapy Revenue and Growth Rate (2017-2021)
7.7.2. Middle East and Africa Oncolytic Virus Immunotherapy Revenue (Million USD) by Countries (2017-2021)
7.7.3. Saudi Arabia
7.7.3.1. Saudi Arabia Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.4. United Arab Emirates
7.7.4.1. United Arab Emirates Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.5. Egypt
7.7.5.1. Egypt Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.6. Nigeria
7.7.6.1. Nigeria Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.7. South Africa
7.7.7.1. South Africa Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.8. Turkey
7.7.8.1. Turkey Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
7.7.9. Rest of Middle East and Africa
7.7.9.1. Rest of Middle East and Africa Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2021)
8. Company Profiles
8.1. Amgen, Inc.
8.1.1. Business Overview
8.1.2. Service Portfolio
8.1.3. Strategic Developments
8.1.4. Financial Overview
8.2. Merck & Co., Inc. (Viralytics Limited)
8.2.1. Business Overview
8.2.2. Service Portfolio
8.2.3. Strategic Developments
8.2.4. Financial Overview
8.3. Shanghai Sunway Biotech Co., Ltd.
8.3.1. Business Overview
8.3.2. Service Portfolio
8.3.3. Strategic Developments
8.3.4. Financial Overview
8.4. TILT Biotherapeutics
8.4.1. Business Overview
8.4.2. Service Portfolio
8.4.3. Strategic Developments
8.4.4. Financial Overview
8.5. Oncorus, Inc.
8.5.1. Business Overview
8.5.2. Service Portfolio
8.5.3. Strategic Developments
8.5.4. Financial Overview
8.6. Replimune Group, Inc.
8.6.1. Business Overview
8.6.2. Service Portfolio
8.6.3. Strategic Developments
8.6.4. Financial Overview
8.7. Oncolys BioPharma, Inc.
8.7.1. Business Overview
8.7.2. Service Portfolio
8.7.3. Strategic Developments
8.7.4. Financial Overview
8.8. Sorrento Therapeutics, Inc.
8.8.1. Business Overview
8.8.2. Service Portfolio
8.8.3. Strategic Developments
8.8.4. Financial Overview
8.9. Oncolytics Biotech, Inc.
8.9.1. Business Overview
8.9.2. Service Portfolio
8.9.3. Strategic Developments
8.9.4. Financial Overview
8.10. SillaJen, Inc.
8.10.1. Business Overview
8.10.2. Service Portfolio
8.10.3. Strategic Developments
8.10.4. Financial Overview
9. Oncolytic Virus Immunotherapy Market Forecast (2022-2027)
9.1. Global Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2022-2027)
9.2. Oncolytic Virus Immunotherapy Market Forecast by Regions (2022-2027)
9.2.1. North America Oncolytic Virus Immunotherapy Market Forecast (2022-2027)
9.2.1.1. United States Oncolytic Virus Immunotherapy Market Forecast (2022-2027)
9.2.1.2. Canada Oncolytic Virus Immunotherapy Market Forecast (2022-2027)
9.2.1.3. Mexico Oncolytic Virus Immunotherapy Market Forecast (2022-2027)
9.2.2. Europe Oncolytic Virus Immunotherapy Market Forecast (2022-2027)
9.2.2.1. Germany Oncolytic Virus Immunotherapy Market Forecast (2022-2027)
9.2.2.2. France Oncolytic Virus Immunotherapy Market Forecast (2022-2027)
9.2.2.3. UK Oncolytic Virus Immunotherapy Market Forecast (2022-2027)
9.2.2.4. Russia Oncolytic Virus Immunotherapy Market Forecast (2022-2027)
9.2.2.5. Italy Oncolytic Virus Immunotherapy Market Forecast (2022-2027)
9.2.2.6. Rest of Europe Oncolytic Virus Immunotherapy Market Forecast (2022-2027)
9.2.3. Asia-Pacific Oncolytic Virus Immunotherapy Market Forecast (2022-2027)
9.2.3.1. China Oncolytic Virus Immunotherapy Market Forecast (2022-2027)
9.2.3.2. Japan Oncolytic Virus Immunotherapy Market Forecast (2022-2027)
9.2.3.3. Korea Oncolytic Virus Immunotherapy Market Forecast (2022-2027)
9.2.3.4. India Oncolytic Virus Immunotherapy Market Forecast (2022-2027)
9.2.3.5. Southeast Asia Oncolytic Virus Immunotherapy Market Forecast (2022-2027)
9.2.3.6. Rest of Asia-Pacific Oncolytic Virus Immunotherapy Market Forecast (2022-2027)
9.2.4. South America Oncolytic Virus Immunotherapy Market Forecast (2022-2027)
9.2.4.1. Brazil Oncolytic Virus Immunotherapy Market Forecast (2022-2027)
9.2.4.2. Argentina Oncolytic Virus Immunotherapy Market Forecast (2022-2027)
9.2.4.3. Columbia Oncolytic Virus Immunotherapy Market Forecast (2022-2027)
9.2.4.4. Rest of South America Oncolytic Virus Immunotherapy Market Forecast (2022-2027)
9.2.5. Middle East and Africa Oncolytic Virus Immunotherapy Market Forecast (2022-2027)
9.2.5.1. Saudi Arabia Oncolytic Virus Immunotherapy Market Forecast (2022-2027)
9.2.5.2. United Arab Emirates Oncolytic Virus Immunotherapy Market Forecast (2022-2027)
9.2.5.3. Egypt Oncolytic Virus Immunotherapy Market Forecast (2022-2027)
9.2.5.4. Nigeria Oncolytic Virus Immunotherapy Market Forecast (2022-2027)
9.2.5.5. South Africa Oncolytic Virus Immunotherapy Market Forecast (2022-2027)
9.2.5.6. Turkey Oncolytic Virus Immunotherapy Market Forecast (2022-2027)
9.2.5.7. Rest of Middle East and Africa Oncolytic Virus Immunotherapy Market Forecast (2022-2027)
9.3. Oncolytic Virus Immunotherapy Market Forecast by Type Of Virus (2022-2027)
9.3.1. Oncolytic Virus Immunotherapy Forecast by Type Of Virus (2022-2027)
9.3.2. Oncolytic Virus Immunotherapy Market Share Forecast by Type Of Virus (2022-2027)
9.4. Oncolytic Virus Immunotherapy Market Forecast by Applications (2022-2027)
9.4.1. Oncolytic Virus Immunotherapy Forecast by Applications (2022-2027)
9.4.2. Oncolytic Virus Immunotherapy Market Share Forecast by Applications (2022-2027)
List of Tables
List of Tables and Figures:
Figure United States Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Canada Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Mexico Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Germany Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure France Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure UK Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Russia Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Italy Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Europe Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure China Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Japan Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Korea Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure India Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Southeast Asia Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Asia-Pacific Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Brazil Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Argentina Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Columbia Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of South America Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Saudi Arabia Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure United Arab Emirates Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Egypt Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Nigeria Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure South Africa Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Turkey Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Middle East and Africa Oncolytic Virus Immunotherapy Revenue (Million USD) and Growth Rate (2017-2027)
Table Global Oncolytic Virus Immunotherapy Revenue and Revenue Share by Type Of Virus (2017-2019)
Figure Global Herpes Simplex Virus Revenue and Growth Rate (2017-2019)
Figure Global Vaccinia Virus Revenue and Growth Rate (2017-2019)
Figure Global Adenovirus Revenue and Growth Rate (2017-2019)
Figure Global Reovirus Revenue and Growth Rate (2017-2019)
Figure Global Others Revenue and Growth Rate (2017-2019)
Table Global Oncolytic Virus Immunotherapy Revenue and Revenue Share by Applications (2017-2019)
Figure Global Melanoma Revenue and Growth Rate (2017-2019)
Figure Global Non-small Cell Lung Cancer [NSCLC] Revenue and Growth Rate (2017-2019)
Figure Global Pancreatic Cancer Revenue and Growth Rate (2017-2019)
Figure Global Breast Cancer Revenue and Growth Rate (2017-2019)
Figure Global Other Revenue and Growth Rate (2017-2019)
Table Global Oncolytic Virus Immunotherapy Revenue by Regions (2017-2019)
Figure North America Oncolytic Virus Immunotherapy Growth Rate (2017-2019)
Figure North America Oncolytic Virus Immunotherapy Revenue and Growth Rate (2017-2019)
Figure North America Oncolytic Virus Immunotherapy by Countries (2017-2019)
Figure North America Oncolytic Virus Immunotherapy Revenue (Million USD) by Countries (2017-2019)
Figure United States Oncolytic Virus Immunotherapy Growth Rate (2017-2019)
Figure United States Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Canada Oncolytic Virus Immunotherapy Growth Rate (2017-2019)
Figure Canada Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Mexico Oncolytic Virus Immunotherapy Growth Rate (2017-2019)
Figure Mexico Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Europe Oncolytic Virus Immunotherapy Growth Rate (2017-2019)
Figure Europe Oncolytic Virus Immunotherapy Revenue and Growth Rate (2017-2019)
Figure Europe Oncolytic Virus Immunotherapy by Countries (2017-2019)
Figure Europe Oncolytic Virus Immunotherapy Revenue (Million USD) by Countries (2017-2019)
Figure Germany Oncolytic Virus Immunotherapy Growth Rate (2017-2019)
Figure Germany Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure France Oncolytic Virus Immunotherapy Growth Rate (2017-2019)
Figure France Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure UK Oncolytic Virus Immunotherapy Growth Rate (2017-2019)
Figure UK Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Russia Oncolytic Virus Immunotherapy Growth Rate (2017-2019)
Figure Russia Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Italy Oncolytic Virus Immunotherapy Growth Rate (2017-2019)
Figure Italy Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Europe Oncolytic Virus Immunotherapy Growth Rate (2017-2019)
Figure Rest of Europe Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Asia-Pacific Oncolytic Virus Immunotherapy Growth Rate (2017-2019)
Figure Asia-Pacific Oncolytic Virus Immunotherapy Revenue and Growth Rate (2017-2019)
Figure Asia-Pacific Oncolytic Virus Immunotherapy by Countries (2017-2019)
Figure Asia-Pacific Oncolytic Virus Immunotherapy Revenue (Million USD) by Countries (2017-2019)
Figure China Oncolytic Virus Immunotherapy Growth Rate (2017-2019)
Figure China Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Japan Oncolytic Virus Immunotherapy Growth Rate (2017-2019)
Figure Japan Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Korea Oncolytic Virus Immunotherapy Growth Rate (2017-2019)
Figure Korea Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure India Oncolytic Virus Immunotherapy Growth Rate (2017-2019)
Figure India Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Southeast Asia Oncolytic Virus Immunotherapy Growth Rate (2017-2019)
Figure Southeast Asia Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Asia-Pacific Oncolytic Virus Immunotherapy Growth Rate (2017-2019)
Figure Rest of Asia-Pacific Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South America Oncolytic Virus Immunotherapy Growth Rate (2017-2019)
Figure South America Oncolytic Virus Immunotherapy Revenue and Growth Rate (2017-2019)
Figure South America Oncolytic Virus Immunotherapy by Countries (2017-2019)
Figure South America Oncolytic Virus Immunotherapy Revenue (Million USD) by Countries (2017-2019)
Figure Brazil Oncolytic Virus Immunotherapy Growth Rate (2017-2019)
Figure Brazil Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Argentina Oncolytic Virus Immunotherapy Growth Rate (2017-2019)
Figure Argentina Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Columbia Oncolytic Virus Immunotherapy Growth Rate (2017-2019)
Figure Columbia Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of South America Oncolytic Virus Immunotherapy Growth Rate (2017-2019)
Figure Rest of South America Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Middle East and Africa Oncolytic Virus Immunotherapy Growth Rate (2017-2019)
Figure Middle East and Africa Oncolytic Virus Immunotherapy Revenue and Growth Rate (2017-2019)
Figure Middle East and Africa Oncolytic Virus Immunotherapy by Countries (2017-2019)
Figure Middle East and Africa Oncolytic Virus Immunotherapy Revenue (Million USD) by Countries (2017-2019)
Figure Saudi Arabia Oncolytic Virus Immunotherapy Growth Rate (2017-2019)
Figure Saudi Arabia Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure United Arab Emirates Oncolytic Virus Immunotherapy Growth Rate (2017-2019)
Figure United Arab Emirates Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Egypt Oncolytic Virus Immunotherapy Growth Rate (2017-2019)
Figure Egypt Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Nigeria Oncolytic Virus Immunotherapy Growth Rate (2017-2019)
Figure Nigeria Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South Africa Oncolytic Virus Immunotherapy Growth Rate (2017-2019)
Figure South Africa Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Turkey Oncolytic Virus Immunotherapy Growth Rate (2017-2019)
Figure Turkey Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Middle East and Africa Oncolytic Virus Immunotherapy Growth Rate (2017-2019)
Figure Rest of Middle East and Africa Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2017-2019)
Table Amgen, Inc. Oncolytic Virus Immunotherapy Financial Overview
Table Merck & Co., Inc. (Viralytics Limited) Oncolytic Virus Immunotherapy Financial Overview
Table Shanghai Sunway Biotech Co., Ltd. Oncolytic Virus Immunotherapy Financial Overview
Table TILT Biotherapeutics Oncolytic Virus Immunotherapy Financial Overview
Table Oncorus, Inc. Oncolytic Virus Immunotherapy Financial Overview
Table Replimune Group, Inc. Oncolytic Virus Immunotherapy Financial Overview
Table Oncolys BioPharma, Inc. Oncolytic Virus Immunotherapy Financial Overview
Table Sorrento Therapeutics, Inc. Oncolytic Virus Immunotherapy Financial Overview
Table Oncolytics Biotech, Inc. Oncolytic Virus Immunotherapy Financial Overview
Table SillaJen, Inc. Oncolytic Virus Immunotherapy Financial Overview
Figure Global Oncolytic Virus Immunotherapy Revenue (Millions USD) and Growth Rate (2019-2027)
Table Oncolytic Virus Immunotherapy Market Forecast by Regions (2019-2027)
Figure North America Oncolytic Virus Immunotherapy Market Forecast (2019-2027)
Figure United States Oncolytic Virus Immunotherapy Market Forecast (2019-2027)
Figure Canada Oncolytic Virus Immunotherapy Market Forecast (2019-2027)
Figure Mexico Oncolytic Virus Immunotherapy Market Forecast (2019-2027)
Figure Europe Oncolytic Virus Immunotherapy Market Forecast (2019-2027)
Figure Germany Oncolytic Virus Immunotherapy Market Forecast (2019-2027)
Figure France Oncolytic Virus Immunotherapy Market Forecast (2019-2027)
Figure UK Oncolytic Virus Immunotherapy Market Forecast (2019-2027)
Figure Russia Oncolytic Virus Immunotherapy Market Forecast (2019-2027)
Figure Italy Oncolytic Virus Immunotherapy Market Forecast (2019-2027)
Figure Rest of Europe Oncolytic Virus Immunotherapy Market Forecast (2019-2027)
Figure Asia-Pacific Oncolytic Virus Immunotherapy Market Forecast (2019-2027)
Figure China Oncolytic Virus Immunotherapy Market Forecast (2019-2027)
Figure Japan Oncolytic Virus Immunotherapy Market Forecast (2019-2027)
Figure Korea Oncolytic Virus Immunotherapy Market Forecast (2019-2027)
Figure India Oncolytic Virus Immunotherapy Market Forecast (2019-2027)
Figure Southeast Asia Oncolytic Virus Immunotherapy Market Forecast (2019-2027)
Figure Rest of Asia-Pacific Oncolytic Virus Immunotherapy Market Forecast (2019-2027)
Figure South America Oncolytic Virus Immunotherapy Market Forecast (2019-2027)
Figure Brazil Oncolytic Virus Immunotherapy Market Forecast (2019-2027)
Figure Argentina Oncolytic Virus Immunotherapy Market Forecast (2019-2027)
Figure Columbia Oncolytic Virus Immunotherapy Market Forecast (2019-2027)
Figure Rest of South America Oncolytic Virus Immunotherapy Market Forecast (2019-2027)
Figure Middle East and Africa Oncolytic Virus Immunotherapy Market Forecast (2019-2027)
Figure Saudi Arabia Oncolytic Virus Immunotherapy Market Forecast (2019-2027)
Figure United Arab Emirates Oncolytic Virus Immunotherapy Market Forecast (2019-2027)
Figure Egypt Oncolytic Virus Immunotherapy Market Forecast (2019-2027)
Figure Nigeria Oncolytic Virus Immunotherapy Market Forecast (2019-2027)
Figure South Africa Oncolytic Virus Immunotherapy Market Forecast (2019-2027)
Figure Turkey Oncolytic Virus Immunotherapy Market Forecast (2019-2027)
Figure Rest of Middle East and Africa Oncolytic Virus Immunotherapy Market Forecast (2019-2027)
Figure Global Oncolytic Virus Immunotherapy Forecast by Type Of Virus (2019-2027)
Figure Global Oncolytic Virus Immunotherapy Market Share Forecast by Type Of Virus (2019-2027)
Figure Global Oncolytic Virus Immunotherapy Forecast by Type Of Virus (2019-2027)
Figure Global Oncolytic Virus Immunotherapy Forecast by Applications (2019-2027)
Figure Global Oncolytic Virus Immunotherapy Market Share Forecast by Applications (2019-2027)
Figure Global Oncolytic Virus Immunotherapy Forecast by Applications (2019-2027)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|